HUTCHMED (China) Limited
Kowloon City
About HUTCHMED (China) Limited
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of over 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed. For more information, please visit: www.hutch med.com or follow us on LinkedIn.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 5,001 – 10,000
- Estimated revenue: $500K – $1M
- Total funding: $220.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2020)
- Ticker: lse:HCM
- Website: hutch-med.com
- Phone: +85221218200
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/hutchmed-china-limited-54241 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.